Prostate cancer is the most prevalent urogenital malignancy.
However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available.
Written by:
Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JA, Cassinello J, García-Donas J, González Del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B. Are you the author?
nstituto Valenciano de Oncología (IVO), Valencia, Spain.
Reference: Crit Rev Oncol Hematol. 2012 Jan 27. Epub ahead of print.
doi: 10.1016/j.critrevonc.2012.01.002
PubMed Abstract
PMID: 22285697
